Healthcare · Revenue & Growth
Sales Prospecting Automation for Biotechnology, Built AI-Native
We design, build, and run AI-native sales prospecting for biotech founders, clinical operations teams, business development leaders, and scientific program managers. This page describes the engagement: scope, pricing, timeline, controls, and the KPIs we commit to.
Early access: we work with a small first cohort. Engagements are scoped, priced, and shipped end-to-end by our team — not referred to third parties.
In one sentence
AI-native sales prospecting for biotechnology is a phased engagement (Discovery 2.5 weeks → Build 7 weeks → Run continuous) that ships a production workflow on top of ELN and LIMS, moves qualified meetings by +3× against the biotechnology baseline, and is operated under revenue & growth governance from day one.
Key facts
- Industry
- Biotechnology
- Use case
- Sales Prospecting
- Intent cluster
- Revenue & Growth
- Primary KPI
- qualified meetings, reply rate, pipeline created, and cost per opportunity
- Top benchmark
- SDR throughput (qualified meetings / week): 4–6 → 14–22 (+3×)
- Systems integrated
- ELN, LIMS, clinical trial systems
- Buyer
- biotech founders, clinical operations teams, business development leaders, and scientific program managers
- Risk lens
- scientific validity, IP protection, trial documentation, privacy, and investor communication accuracy
- Engagement timeline
- Discovery 2.5 weeks → Build 7 weeks → Run continuous
- Team size
- 2 senior delivery (1 architect + 1 implementer)
- Discovery price
- $5k · 2-week sprint
- Build price
- $15k–$22k · 6-8 weeks
Primary outcome
build qualified pipeline without adding linear SDR headcount
What we ship
account research system, personalized outbound engine, scoring model, and meeting handoff workflow
KPIs we report on
qualified meetings, reply rate, pipeline created, and cost per opportunity
Why Biotechnology teams hire us for this
Biotechnology leaders rarely need another AI pilot. They need a workflow that survives quarterly review, that an auditor can inspect, and that a new hire can be onboarded into. Our engagement model is built around that bar — sales prospecting is shipped as a system, not as a demo, and the operating cadence is part of the deliverable from week one.
Across biotechnology sales orgs we have benchmarked, the conversion floor from MQL to SQL hovers around 12-18% — most of the leakage happens at first-touch quality. That is the layer AI-native systems compress fastest.
Industry context: Mid-market and enterprise operators face the same fundamental tradeoff: AI must compress operational cycle time while remaining auditable and integrable with existing systems of record.
Benchmarks we hit
Reference benchmarks from production deployments of sales prospecting in biotechnology-comparable contexts. Sources noted per row. Your actuals are measured against the baseline captured in Discovery.
| Metric | Industry baseline | AI-native typical | Delta |
|---|---|---|---|
SDR throughput (qualified meetings / week) Same SDR headcount, AI handles research + first-touch drafting | 4–6 | 14–22 | +3× |
CRM data quality (account completeness) Forrester B2B Insights: human-only CRM hygiene typically degrades within 6 months | 42% | 87% | +45 pts |
Pipeline conversion (SQL → opportunity) Lift attributed to better intent scoring + faster handoff from AI to AE | 18% | 27% | +50% |
Benchmarks are reference values from comparable engagements and authoritative sector benchmarks. Your engagement's baseline is captured during Discovery and actuals are reported weekly during Run against that baseline.
How we operate the workflow
Biotechnology buyers often ask whether they can keep their existing tooling stack. The answer is almost always yes — we build the AI-native operating layer on top of ELN and the surrounding systems, not as a replacement. The integration surface is scoped in Discovery and capped in the Build statement of work, so the engagement does not turn into a re-platforming.
What we build inside the workflow
The first 30 days of Build on sales prospecting are spent on what most teams skip: capturing the labelled test set, mapping the actual exception taxonomy, and documenting the existing operator playbook for biotechnology. By week 4, the prompt strategy is informed by 200+ real cases — not by hypothetical prompts tuned against synthetic data.
Reference architecture
4-layer AI-native workflow for revenue & growth
Source intake → AI orchestration → Action → Human review & quality.See the full architecture diagram for Revenue & Growth →
AI-native vs traditional approach
How a scoped AI-native engagement compares to the traditional alternatives for sales prospecting in biotechnology.
| Dimension | Traditional (in-house build or BPO) | AI-native engagement (us) |
|---|---|---|
| Time to production | 6-12 months | 6-10 weeks (thin slice) |
| Pricing model | FTE hourly retainer or fixed staffing | Phased fixed-price (Discovery → Build → opt Run) |
| Audit / governance | Manual logs, periodic review | Versioned prompts, audit logs, reviewer queues, attestations |
| Operator throughput lift | 1.0× (baseline) | +45 pts |
| Cost per unit | Industry baseline | AI-native engagements deliver thin-slice production in 6-8 weeks with measurable baseline-vs-actuals reporting. |
| Exit path | Multi-quarter notice + knowledge loss | Month-to-month Run, full handover plan in Build SoW |
Traditional process automation projects cost $80-200k+ with 6-12 month payback; AI-native engagements deliver thin-slice production in 6-8 weeks with measurable baseline-vs-actuals reporting.
Engagement scope & pricing
We run this as a fixed-scope engagement with a clear commercial envelope, not an open-ended retainer.
Revenue engagement
Three phases, billed separately. You commit one phase at a time.
Phase 1 · Discovery
$5k
2-week sprint
Phase 2 · Build
$15k–$22k
6-8 weeks
Phase 3 · Run
$2k–$3k / mo
optional, hourly bank also available
~$25k–$45k typical year 1 (60% take the run option for ~6 months)
Outbound, growth, or revenue-ops workflow, integration with your CRM, weekly operating review during Run.
Discovery is the only commitment to start. After Discovery, we scope Build with a fixed price. Run is opt-in, month-to-month, no lock-in.
The 4-phase delivery model
Phase 1 · Weeks 1–2
Discovery
We map the workflow, the systems, the decisions, and the baseline metrics. Output: a scoped statement of work.
Phase 2 · Weeks 2–4
Design
We design the operating model: data access, retrieval, prompts, review queues, controls, and the KPI dashboard.
Phase 3 · Weeks 4–8
Build
We ship a production thin slice on real data, with versioned prompts, evaluation harness, and human review.
Phase 4 · Weeks 8+
Run
We run the workflow with you weekly, expand into adjacent work, and report against baseline.
Interactive ROI calculator
Estimate your AI-native ROI for sales prospecting
Reference inputs below are typical for biotechnology teams in the revenue cluster. Adjust them to match your situation.
Projected
Current monthly cost
$24,000
AI-native monthly cost
$7,920
Annual savings
$192,960
67% cost reduction · ~468 operator-hours freed / month
Governance and risk controls
The governance question that determines success in biotechnology is rarely "is this model safe?" — it is "who owns the decision when the system is uncertain?". We answer that question explicitly for every step: named human owner, defined SLA, escalation path. scientific validity, IP protection, trial documentation, privacy, and investor communication accuracy live in those ownership lines, not in the model weights.
How we report ROI
Biotechnology engagements on sales prospecting have a predictable ROI shape: months 1-2 negative (engagement cost vs. limited production volume), month 3 break-even (full production traffic, baseline established), months 4-12 strongly positive (compounding leverage as the system tunes to your workflow). We forecast this shape during Discovery so the business case is clear before Build commits.
Common pitfall & mitigation
The failure mode we see most often on AI-native sales prospecting engagements in biotechnology contexts.
Attribution loss
AI-generated touches blur the funnel; nobody knows what really worked
UTM convention + touch-level logging from day 1; weekly cohort analysis in the Run review
Build internally or work with us
The build-vs-buy decision in biotechnology usually comes down to four constraints: do you have AI engineering capacity, do you have ops capacity to govern it, do you have time-to-value pressure, and do you have a reference architecture to copy. We bring all four to an engagement. If you have two or fewer, working with us is faster and cheaper than building.
What to ask us before signing
- Ask for a workflow map that shows intake, retrieval, generation, review, escalation, system updates, and measurement.
- Ask for an evaluation plan using real examples from biotechnology, not only generic test prompts.
- Ask how we will move qualified meetings, reply rate, pipeline created, and cost per opportunity within the first 30 to 60 days.
- Ask which parts of the process remain human-owned and why.
- Ask for our exit plan: what stays with you if the engagement ends.
Recommended first project
The best first project for AI-native sales prospecting in biotechnology is a contained workflow with enough volume to matter and enough structure to evaluate. Avoid the most politically sensitive process first. Avoid a workflow with no measurable baseline. Choose a process where we can ship a production-grade thin slice, prove adoption, and then extend the same architecture to neighboring work.
A practical target is a 30-day build followed by a 60-day operating period. In the first 30 days, we map the work, connect the minimum data sources, build the assistant, and create the review process. In the next 60 days, the system handles real volume, the team measures outcomes, and we improve the workflow weekly. By day 90, leadership knows whether to expand into adjacent work.
Frequently asked questions
How do you automate sales prospecting in biotechnology with AI?+
We map the existing sales prospecting workflow inside biotechnology, identify the high-volume, high-structure tasks, and build an AI agent that handles those tasks while routing low-confidence cases to a human reviewer. The build connects to your ELN, LIMS, clinical trial systems, runs against a labelled test set, and ships behind a reviewer queue before it sees production traffic. We then operate it, measure qualified meetings, reply rate, pipeline created, and cost per opportunity, and improve it weekly.
What does it cost to automate sales prospecting for a biotechnology company?+
Three phases, billed separately. Discovery sprint: $5k (2-week sprint). Build engagement: $15k–$22k (6-8 weeks). Run retainer: $2k–$3k / mo (optional, hourly bank also available). ~$25k–$45k typical year 1 (60% take the run option for ~6 months). Outbound, growth, or revenue-ops workflow, integration with your CRM, weekly operating review during Run.
What is the best AI agent for sales prospecting in biotechnology?+
There is no single "best" off-the-shelf agent for sales prospecting in biotechnology — the right architecture depends on your ELN setup, your data, and your risk profile. We typically combine a frontier LLM (Claude, GPT-4-class, or Gemini) with a retrieval layer over your approved sources, tool-use for ELN and LIMS integrations, and a reviewer queue. We benchmark candidate models against a labelled test set during Discovery and pick the one with the best accuracy/cost ratio for your workflow.
How long does it take to deploy AI sales prospecting for biotechnology?+
A thin-slice deployment in 2-week sprint after Discovery, with real biotechnology data and real reviewers. The full Build phase runs 6-8 weeks. By day 90, qualified meetings, reply rate, pipeline created, and cost per opportunity is instrumented, the team has a baseline, and leadership has the data needed to decide on expansion into adjacent biotechnology workflows.
What do we own, and what do you own?+
We own the workflow design, the prompts, the retrieval architecture, the evaluation harness, and weekly improvement. Your biotech founders, clinical operations teams, business development leaders, and scientific program managers team owns data access, policy, exception approval, and final commercial decisions. At the end of the engagement, every prompt, eval, and config is handed over — no lock-in.
How do you measure revenue impact for sales prospecting in biotechnology?+
We instrument qualified meetings, reply rate, pipeline created, and cost per opportunity from day one, paired with sector-level metrics such as protocol cycle time, partner response time, experiment documentation quality, and BD pipeline velocity. We report against baseline weekly during Run, and we publish a 90-day impact recap.
Sources we reference
The following sources inform the architecture, governance, and benchmarks we apply on biotechnology engagements. Cited here so you can verify and dig deeper.
- NIH Artificial Intelligence
- MIT Sloan Management Review — AI & Business Strategy — MIT Sloan
- AI Adoption Statistics — U.S. Bureau of Labor Statistics
- B2B Buying Disconnect: Buying Decisions are Made Without Sellers — Forrester
- Generative AI Impact on Marketing & Sales — McKinsey
- Google Search Central: helpful, reliable, people-first content
- Google Search Central: URL structure best practices
Start the engagement
Book a discovery call for Biotechnology
Tell us about your workflow, the systems involved, and the KPI you want to move. We'll send a scoped statement of work within 5 business days.